國家衛生研究院 NHRI:Item 3990099045/14975

NHRI > National Institute of Infectious Diseases and Vaccinology > Huey-Kang Sytwu > Periodical Articles > Item 3990099045/14975

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14975

Title:	Interleukin 26 induces macrophage IL-9 expression in rheumatoid arthritis
Authors:	Wang, YH;Peng, YJ;Liu, FC;Lin, GJ;Huang, SH;Sytwu, HK;Cheng, CP
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	Rheumatoid arthritis (RA) is an autoimmune disease with chronic inflammation, bone erosion, and joint deformation. Synovial tissue in RA patients is full of proinflammatory cytokines and infiltrated immune cells, such as T help (Th) 9, Th17, macrophages, and osteoclasts. Recent reports emphasized a new member of the interleukin (IL)-10 family, IL-26, an inducer of IL-17A that is overexpressed in RA patients. Our previous works found that IL-26 inhibits osteoclastogenesis and conducts monocyte differentiation toward M1 macrophages. In this study, we aimed to clarify the effect of IL-26 on macrophages linking to Th9 and Th17 in IL-9 and IL-17 expression and downstream signal transduction. Murine and human macrophage cell lines and primary culture cells were used and stimulated by IL26. Cytokines expressions were evaluated by flow cytometry. Signal transduction and transcription factors expression were detected by Western blot and real time-PCR. Our results show that IL-26 and IL-9 colocalized in macrophage in RA synovium. IL-26 directly induces macrophage inflammatory cytokines IL-9 and IL-17A expression. IL-26 increases the IL-9 and IL-17A upstream mechanisms IRF4 and RelB expression. Moreover, the AKT-FoxO1 pathway is also activated by IL-26 in IL-9 and IL-17A expressing macrophage. Blockage of AKT phosphorylation enhances IL-26 stimulating IL-9-producing macrophage cells. In conclusion, our results support that IL-26 promotes IL-9- and IL-17-expressing macrophage and might initiate IL-9- and IL-17-related adaptive immunity in rheumatoid arthritis. Targeting IL-26 may a potential therapeutic strategy for rheumatoid arthritis or other IL-9 plus IL-17 dominant diseases.
Date:	2023-04-19
Relation:	International Journal of Molecular Sciences. 2023 Apr 19;24(8):Article number 7526.
Link to:	http://dx.doi.org/10.3390/ijms24087526
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1422-0067&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000977526000001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85157987002
Appears in Collections:	[Huey-Kang Sytwu] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB37108686.pdf		7567Kb	Adobe PDF	128	View/Open

Loading...